181 related articles for article (PubMed ID: 19709637)
1. Tumor regression after systemic administration of tocotrienol entrapped in tumor-targeted vesicles.
Fu JY; Blatchford DR; Tetley L; Dufès C
J Control Release; 2009 Dec; 140(2):95-9. PubMed ID: 19709637
[TBL] [Abstract][Full Text] [Related]
2. Novel tocotrienol-entrapping vesicles can eradicate solid tumors after intravenous administration.
Fu JY; Zhang W; Blatchford DR; Tetley L; McConnell G; Dufès C
J Control Release; 2011 Aug; 154(1):20-6. PubMed ID: 21539872
[TBL] [Abstract][Full Text] [Related]
3. Tumor regression after systemic administration of a novel tumor-targeted gene delivery system carrying a therapeutic plasmid DNA.
Koppu S; Oh YJ; Edrada-Ebel R; Blatchford DR; Tetley L; Tate RJ; Dufès C
J Control Release; 2010 Apr; 143(2):215-21. PubMed ID: 19944722
[TBL] [Abstract][Full Text] [Related]
4. Delivery of the vitamin E compound tocotrienol to cancer cells.
Dufès C
Ther Deliv; 2011 Nov; 2(11):1385-9. PubMed ID: 22826870
[TBL] [Abstract][Full Text] [Related]
5. Polyethylene glycol-complexed cationic liposome for enhanced cellular uptake and anticancer activity.
Jung SH; Jung SH; Seong H; Cho SH; Jeong KS; Shin BC
Int J Pharm; 2009 Dec; 382(1-2):254-61. PubMed ID: 19666094
[TBL] [Abstract][Full Text] [Related]
6. Targeted delivery of doxorubicin using stealth liposomes modified with transferrin.
Li X; Ding L; Xu Y; Wang Y; Ping Q
Int J Pharm; 2009 May; 373(1-2):116-23. PubMed ID: 19429296
[TBL] [Abstract][Full Text] [Related]
7. Superior antitumor efficiency of cisplatin-loaded nanoparticles by intratumoral delivery with decreased tumor metabolism rate.
Li X; Li R; Qian X; Ding Y; Tu Y; Guo R; Hu Y; Jiang X; Guo W; Liu B
Eur J Pharm Biopharm; 2008 Nov; 70(3):726-34. PubMed ID: 18634874
[TBL] [Abstract][Full Text] [Related]
8. Long-circulating liposome-encapsulated ganciclovir enhances the efficacy of HSV-TK suicide gene therapy.
Kajiwara E; Kawano K; Hattori Y; Fukushima M; Hayashi K; Maitani Y
J Control Release; 2007 Jul; 120(1-2):104-10. PubMed ID: 17509714
[TBL] [Abstract][Full Text] [Related]
9. Tumor regression after intravenous administration of targeted vesicles entrapping the vitamin E α-tocotrienol.
Karim R; Somani S; Al Robaian M; Mullin M; Amor R; McConnell G; Dufès C
J Control Release; 2017 Jan; 246():79-87. PubMed ID: 27993600
[TBL] [Abstract][Full Text] [Related]
10. Preparation, characterization, and anticancer effects of simvastatin-tocotrienol lipid nanoparticles.
Ali H; Shirode AB; Sylvester PW; Nazzal S
Int J Pharm; 2010 Apr; 389(1-2):223-31. PubMed ID: 20123009
[TBL] [Abstract][Full Text] [Related]
11. In vivo antitumor effects of chitosan-conjugated docetaxel after oral administration.
Lee E; Kim H; Lee IH; Jon S
J Control Release; 2009 Dec; 140(2):79-85. PubMed ID: 19712714
[TBL] [Abstract][Full Text] [Related]
12. The metal-binding domain of IGFBP-3 selectively delivers therapeutic molecules into cancer cells.
Huq A; Singh B; Meeker T; Mascarenhas D
Anticancer Drugs; 2009 Jan; 20(1):21-31. PubMed ID: 19342998
[TBL] [Abstract][Full Text] [Related]
13. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models.
Hoch U; Lynch J; Sato Y; Kashimoto S; Kajikawa F; Furutani Y; Silverman JA
Cancer Chemother Pharmacol; 2009 Jun; 64(1):53-65. PubMed ID: 18931998
[TBL] [Abstract][Full Text] [Related]
14. Tumor regression and modulation of gene expression via tumor-targeted tocotrienol niosomes.
Tan DM; Fu JY; Wong FS; Er HM; Chen YS; Nesaretnam K
Nanomedicine (Lond); 2017 Oct; 12(20):2487-2502. PubMed ID: 28972460
[TBL] [Abstract][Full Text] [Related]
15. Antitumor activity of the tea polyphenol epigallocatechin-3-gallate encapsulated in targeted vesicles after intravenous administration.
Lemarié F; Chang CW; Blatchford DR; Amor R; Norris G; Tetley L; McConnell G; Dufès C
Nanomedicine (Lond); 2013 Feb; 8(2):181-92. PubMed ID: 22891867
[TBL] [Abstract][Full Text] [Related]
16. Transferrin coupled vesicular system for intracellular drug delivery for the treatment of cancer: development and characterization.
Vaidya B; Vyas SP
J Drug Target; 2012 May; 20(4):372-80. PubMed ID: 22339366
[TBL] [Abstract][Full Text] [Related]
17. Tumor cell targeting of transferrin-PEG-TNF-alpha conjugate via a receptor-mediated delivery system: design, synthesis, and biological evaluation.
Jiang YY; Liu C; Hong MH; Zhu SJ; Pei YY
Bioconjug Chem; 2007; 18(1):41-9. PubMed ID: 17226956
[TBL] [Abstract][Full Text] [Related]
18. Systemic delivery of liposomal short-chain ceramide limits solid tumor growth in murine models of breast adenocarcinoma.
Stover TC; Sharma A; Robertson GP; Kester M
Clin Cancer Res; 2005 May; 11(9):3465-74. PubMed ID: 15867249
[TBL] [Abstract][Full Text] [Related]
19. Ligand-conjugated mesoporous silica nanorattles based on enzyme targeted prodrug delivery system for effective lung cancer therapy.
Sundarraj S; Thangam R; Sujitha MV; Vimala K; Kannan S
Toxicol Appl Pharmacol; 2014 Mar; 275(3):232-43. PubMed ID: 24467950
[TBL] [Abstract][Full Text] [Related]
20. In vitro and in vivo characterization of a combination chemotherapy formulation consisting of vinorelbine and phosphatidylserine.
Webb MS; Johnstone S; Morris TJ; Kennedy A; Gallagher R; Harasym N; Harasym T; Shew CR; Tardi P; Dragowska WH; Mayer LD; Bally MB
Eur J Pharm Biopharm; 2007 Mar; 65(3):289-99. PubMed ID: 17123800
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
